Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 22, 2008. The report details a specific corporate action regarding the company's share capital executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase and capital structure data:
- Shares Purchased: 2,830,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,212.1166 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.04% of total voting rights).
- Shares in Issue: 5,243,315,373 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,830,000 shares purchased on July 22, 2008. This transaction increased the proportion of shares held in Treasury to 9.04% of total voting rights. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules. No specific risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the total number of shares in issue (5,243,315,373) for accurate calculation of ownership percentages under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (9.04%).
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for revenue and earnings data.